Omnicell (NASDAQ:OMCL) Upgraded to “Buy” by StockNews.com

by · The Cerbat Gem

StockNews.com upgraded shares of Omnicell (NASDAQ:OMCL – Free Report) from a hold rating to a buy rating in a report issued on Thursday morning.

Several other equities analysts have also commented on OMCL. JPMorgan Chase & Co. increased their price objective on shares of Omnicell from $26.00 to $37.00 and gave the company a neutral rating in a research report on Friday, August 23rd. Barclays raised shares of Omnicell from an underweight rating to an equal weight rating and raised their price target for the stock from $26.00 to $39.00 in a research report on Friday, August 2nd. Bank of America raised their price target on shares of Omnicell from $34.00 to $44.00 and gave the stock a buy rating in a research report on Friday, August 2nd. Wells Fargo & Company raised their price target on shares of Omnicell from $26.00 to $30.00 and gave the stock an equal weight rating in a research report on Friday, August 2nd. Finally, Benchmark reissued a buy rating and set a $48.00 price target on shares of Omnicell in a research report on Wednesday. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of Moderate Buy and an average price target of $39.50.

View Our Latest Stock Report on Omnicell

Omnicell Price Performance

Shares of Omnicell stock traded up $0.29 during midday trading on Thursday, hitting $42.41. The company had a trading volume of 20,996 shares, compared to its average volume of 522,031. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.22 and a current ratio of 2.45. The company has a fifty day simple moving average of $42.91 and a 200 day simple moving average of $33.62. Omnicell has a 12-month low of $25.12 and a 12-month high of $45.84.

Omnicell (NASDAQ:OMCL – Get Free Report) last announced its quarterly earnings data on Thursday, August 1st. The company reported $0.51 EPS for the quarter, beating the consensus estimate of $0.14 by $0.37. The firm had revenue of $276.80 million during the quarter, compared to analyst estimates of $254.41 million. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. Omnicell’s revenue was down 7.4% on a year-over-year basis. During the same period last year, the firm posted $0.29 EPS. As a group, analysts predict that Omnicell will post 0.64 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Omnicell

A number of institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC boosted its stake in Omnicell by 78.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock worth $55,000 after purchasing an additional 553 shares during the last quarter. Nisa Investment Advisors LLC lifted its position in Omnicell by 248.8% in the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock valued at $38,000 after buying an additional 1,000 shares during the last quarter. EntryPoint Capital LLC lifted its position in Omnicell by 121.2% in the first quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock valued at $72,000 after buying an additional 1,345 shares during the last quarter. CWM LLC lifted its position in shares of Omnicell by 68.2% during the second quarter. CWM LLC now owns 3,048 shares of the company’s stock worth $83,000 after purchasing an additional 1,236 shares in the last quarter. Finally, Benjamin Edwards Inc. lifted its position in shares of Omnicell by 36.4% during the first quarter. Benjamin Edwards Inc. now owns 3,253 shares of the company’s stock worth $95,000 after purchasing an additional 868 shares in the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

About Omnicell

(Get Free Report)

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

Further Reading